Survival probabilities in ET, PV, and MF according to frailty status
| Essential thrombocythemia . | Fit, N = 1731 . | Prefrail, N = 2504 . | Frail, N = 873 . | P value . |
|---|---|---|---|---|
| Follow-up in y | <.001 | |||
| Mean (SD) | 5.39 (3.52) | 4.63 (3.30) | 3.02 (2.69) | |
| Median (IQR) | 4.74 (2.60-7.47) | 3.88 (2.16-6.34) | 2.29 (0.87-4.62) | |
| Range | 0.00-16.90 | 0.01-17.08 | 0.00-14.62 | |
| Vital status, n (%) | <.001 | |||
| Alive/censored | 1489 (86) | 1673 (67) | 296 (34) | |
| Died | 242 (14) | 831 (33) | 577 (66) | |
| Kaplan-Meir survival probabilities, % (95% CI) | <.001 | |||
| 12 mo | 98 (97-98) | 92 (91-93) | 74 (71-77) | |
| 24 mo | 96 (95-97) | 87 (86-89) | 60 (57-64) | |
| 36 mo | 94 (93-95) | 82 (81-84) | 52 (49-56) | |
| 48 mo | 92 (90-93) | 76 (75-78) | 44 (41-48) | |
| 60 mo | 89 (88-91) | 71 (69-73) | 37 (33-41) |
| Essential thrombocythemia . | Fit, N = 1731 . | Prefrail, N = 2504 . | Frail, N = 873 . | P value . |
|---|---|---|---|---|
| Follow-up in y | <.001 | |||
| Mean (SD) | 5.39 (3.52) | 4.63 (3.30) | 3.02 (2.69) | |
| Median (IQR) | 4.74 (2.60-7.47) | 3.88 (2.16-6.34) | 2.29 (0.87-4.62) | |
| Range | 0.00-16.90 | 0.01-17.08 | 0.00-14.62 | |
| Vital status, n (%) | <.001 | |||
| Alive/censored | 1489 (86) | 1673 (67) | 296 (34) | |
| Died | 242 (14) | 831 (33) | 577 (66) | |
| Kaplan-Meir survival probabilities, % (95% CI) | <.001 | |||
| 12 mo | 98 (97-98) | 92 (91-93) | 74 (71-77) | |
| 24 mo | 96 (95-97) | 87 (86-89) | 60 (57-64) | |
| 36 mo | 94 (93-95) | 82 (81-84) | 52 (49-56) | |
| 48 mo | 92 (90-93) | 76 (75-78) | 44 (41-48) | |
| 60 mo | 89 (88-91) | 71 (69-73) | 37 (33-41) |
| Polycythemia vera . | Fit, N = 1237 . | Prefrail, N = 2034 . | Frail, N = 572 . | P value . |
|---|---|---|---|---|
| Follow-up in y | <.001 | |||
| Mean (SD) | 5.10 (3.40) | 4.85 (3.23) | 3.40 (2.90) | |
| Median (IQR) | 4.46 (2.28-7.23) | 4.19 (2.26-7.03) | 2.81 (1.12-5.05) | |
| Range | 0.00-16.98 | 0.01-17.26 | 0.00-15.76 | |
| Vital status, n (%) | <.001 | |||
| Alive/censored | 1026 (83) | 1372 (67) | 215 (38) | |
| Died | 211 (17) | 662 (33) | 357 (62) | |
| Kaplan-Meir survival probabilities, % (95% CI) | <.001 | |||
| 12 mo | 97 (96-98) | 93 (91-94) | 78 (75-81) | |
| 24 mo | 94 (93-96) | 88 (87-90) | 64 (60-68) | |
| 36 mo | 92 (91-94) | 83 (81-85) | 58 (54-62) | |
| 48 mo | 90 (88-91) | 78 (76-80) | 48 (44-53) | |
| 60 mo | 86 (84-89) | 73 (71-75) | 42 (38-47) |
| Polycythemia vera . | Fit, N = 1237 . | Prefrail, N = 2034 . | Frail, N = 572 . | P value . |
|---|---|---|---|---|
| Follow-up in y | <.001 | |||
| Mean (SD) | 5.10 (3.40) | 4.85 (3.23) | 3.40 (2.90) | |
| Median (IQR) | 4.46 (2.28-7.23) | 4.19 (2.26-7.03) | 2.81 (1.12-5.05) | |
| Range | 0.00-16.98 | 0.01-17.26 | 0.00-15.76 | |
| Vital status, n (%) | <.001 | |||
| Alive/censored | 1026 (83) | 1372 (67) | 215 (38) | |
| Died | 211 (17) | 662 (33) | 357 (62) | |
| Kaplan-Meir survival probabilities, % (95% CI) | <.001 | |||
| 12 mo | 97 (96-98) | 93 (91-94) | 78 (75-81) | |
| 24 mo | 94 (93-96) | 88 (87-90) | 64 (60-68) | |
| 36 mo | 92 (91-94) | 83 (81-85) | 58 (54-62) | |
| 48 mo | 90 (88-91) | 78 (76-80) | 48 (44-53) | |
| 60 mo | 86 (84-89) | 73 (71-75) | 42 (38-47) |
| Myelofibrosis . | Fit, N = 396 . | Prefrail, N = 739 . | Frail, N= 250 . | P value . |
|---|---|---|---|---|
| Follow-up in y | <.001 | |||
| Mean (SD) | 4.38 (3.30) | 3.74 (2.96) | 2.10 (2.12) | |
| Median (IQR) | 3.60 (1.89-6.01) | 3.10 (1.47-5.39) | 1.44 (0.47-3.13) | |
| Range | 0.02-16.43 | 0.00-16.39 | 0.00-10.76 | |
| Vital status, n (%) | <.001 | |||
| Alive/censored | 220 (56) | 240 (32) | 40 (16) | |
| Died | 176 (44) | 499 (68) | 210 (84) | |
| Kaplan-Meir survival probabilities, % (95% CI) | <.001 | |||
| 12 mo | 89 (86-92) | 84 (81-86) | 62 (56-68) | |
| 24 mo | 82 (78-86) | 72 (68-75) | 41 (36-48) | |
| 36 mo | 74 (69-78) | 60 (57-64) | 31 (25-37) | |
| 48 mo | 68 (63-73) | 51 (47-55) | 22 (17-29) | |
| 60 mo | 59 (54-65) | 41 (37-45) | 16 (12-22) |
| Myelofibrosis . | Fit, N = 396 . | Prefrail, N = 739 . | Frail, N= 250 . | P value . |
|---|---|---|---|---|
| Follow-up in y | <.001 | |||
| Mean (SD) | 4.38 (3.30) | 3.74 (2.96) | 2.10 (2.12) | |
| Median (IQR) | 3.60 (1.89-6.01) | 3.10 (1.47-5.39) | 1.44 (0.47-3.13) | |
| Range | 0.02-16.43 | 0.00-16.39 | 0.00-10.76 | |
| Vital status, n (%) | <.001 | |||
| Alive/censored | 220 (56) | 240 (32) | 40 (16) | |
| Died | 176 (44) | 499 (68) | 210 (84) | |
| Kaplan-Meir survival probabilities, % (95% CI) | <.001 | |||
| 12 mo | 89 (86-92) | 84 (81-86) | 62 (56-68) | |
| 24 mo | 82 (78-86) | 72 (68-75) | 41 (36-48) | |
| 36 mo | 74 (69-78) | 60 (57-64) | 31 (25-37) | |
| 48 mo | 68 (63-73) | 51 (47-55) | 22 (17-29) | |
| 60 mo | 59 (54-65) | 41 (37-45) | 16 (12-22) |
CI, confidence interval; SD, standard deviation.